KR20210037186A - A pharmaceutical composition for the prevention and treatment of alopecia comprising boehmite as a effective ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing, treating or alleviating hair loss, and promoting hair sprouting and hair growth, comprising boehmite as an active component. The boehmite particles according to the present invention have no side effects when treating hair loss, and have excellent hair growth effects in a short time, so that it is possible to be used as pharmaceuticals, as well as quasi-drugs, cosmetics, and health functional foods.

Description

A pharmaceutical composition for preventing or treating hair loss containing boehmite as an active ingredient {A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALOPECIA COMPRISING BOEHMITE AS A EFFECTIVE INGREDIENT}

The present invention relates to a composition for preventing, treating or improving hair loss, promoting hair growth and hair growth, comprising boehmite as an active ingredient. The boehmite particles according to the present invention have no side effects during the treatment of hair loss, and have excellent hair growth effect even in a short time, so that they can be used as pharmaceuticals, as well as quasi-drugs, cosmetics, and health functional foods.

Hair loss refers to a condition in which hair has fallen out and is sexual or disappeared, and the number of human hairs is about 100,000 to 150,000, and has its own cycles of growth and dropouts such as anagen, catagen, and telogen. Repeatedly, an average of 100 hairs per day are naturally depilated [1]. The mechanism of hair loss has not been accurately identified, but studies so far have shown that excessive sebum production due to abnormalities in the circulatory system such as hormonal imbalance, autonomic nervous system and blood circulation disorders, nutrient deficiency of hair roots, allergies, bacterial infection, genetics. Environmental factors such as environmental factors, mental stress, air pollution or food, and aging are presumed to be the causes. Alopecia has occurred only in the middle and elderly in the past, but recently, it is frequently occurring in young people in their 20s to 30s.

The most common type of male alopecia is male pattern baldness or alopecia, which develops gradually over the years, starts most clearly at the crown of the head and progresses to the forehead. In the case of female hair loss, it occurs in a more dispersed form as the thickness of the hair becomes thinner, and it often appears after menopause [2]. Many studies are being conducted to alleviate or treat alopecia. In particular, research has been conducted in the cosmetic or pharmaceutical industry for a long time in the field of cosmetics or pharmaceutical industry to stimulate hair growth or to develop new substances to alleviate hair loss. Drug therapy and hair transplantation using accelerators have been developed. Currently, 2,4-diamino-6-piperidinopyrimidine-3-oxide (aka'Minoxidil (MNX)' formulation), which has been approved by the FDA, is the most commonly used drug for hair loss treatment and And finasteride, a specific inhibitor of type II 5α-reductase.

MNX formulations are drugs that induce hair growth by increasing blood flow through the vasodilating effect and supplying nutrients to the hair roots, and are known to be particularly effective in relieving hair loss symptoms in the kiln area. It is marketed under the trade name Rogaine (trade name of Rogaine Pharmacia & Upjohn Company). Rogaine is known to reduce hair loss and promote hair growth by up to 10% in men suffering from androgenetic alopecia, but it must be applied directly to the scalp area and used regularly over a long period of time, and areas other than the kiln area There is a disadvantage in that it does not exert a very good effect on the hair loss. Medicines using finasteride as an active ingredient are marketed under the brand name Propecia (trade name of Propecia, Merck & Co., Inc.), which is a pill for oral administration, which inhibits the function of II-7 type 5α-reductase to testosterone (Testosterone). ) Is known to inhibit hair loss by preventing conversion to dihydrotestosterone (DHT). However, it also requires constant and regular administration, and some patients have reported a problem of having side effects such as decreased libido and erectile dysfunction. Therefore, it is required to develop a compound that prevents hair loss and promotes hair growth, which is superior to other natural plant extract compositions or hair transplant methods, and has excellent drug delivery power and stability, while overcoming the problems of the MNX formulation or finasteride formulation. Has been.

Prior literature

1. Courtois, M., et al., Hair cycle and alopecia. Skin Pharmacology and Physiology, 1994. 7(1-2): p. 84-89.

2. Lee, W.-S., et al., A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. Journal of the American Academy of Dermatology, 2007. 57(1): p. 37-46.

In the present invention, as a result of earnest efforts to develop a substance capable of preventing hair loss and promoting hair growth without side effects, Boehmite (AlO(OH)) is a gene that positively affects cell proliferation and hair follicle differentiation growth. It was very effective in increasing the expression, and it was confirmed that the tissue can be grown by stimulating the hair follicle tissue in the resting period, and the present invention was completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating hair loss comprising boehmite as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition, cosmetic composition, and food composition for preventing or improving hair loss comprising boehmite as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for promoting hair growth or hair growth, a quasi-drug composition, a cosmetic composition, and a food composition comprising boehmite as an active ingredient.

The composition containing boehmite according to the present invention is a cell viability and Alkaline phosphatase (ALP) activation and cell proliferation marker PCNA (Proliferating cell nuclear antigen) in a cell growth evaluation experiment using human dermal papilla cells (hDPCs). ), and as a result of measuring the expression level of hair growth promotion-related mRNA in hDPCs, ALP, β-catenin, CyclinD1, Hey1, Lef-1 (Lymphoid enhancer binding factor-1) , Shh (Sonic hedgehog), Sox2, Versican, and VEGF (Vascular endothelial growth factor) was confirmed to increase the amount of mRNA expression. In addition, as a result of evaluating the growth of hair follicles using the telogen to anagen transition animal model, it was confirmed that the tissue can be grown by stimulating the follicle tissue in the resting period, and thereby, the time to reach the follicle tissue in the resting period can be accelerated.

Therefore, the composition for preventing hair loss or promoting hair growth comprising boehmite according to the present invention as an active ingredient has no side effects when treating hair loss, and has excellent hair growth effect even in a short time, so that it can be used as a medicine, as well as quasi-drugs, cosmetics, and health. It is expected to be useful in functional foods.

1 shows the results of cell growth evaluation by Jaielite SBM using human dermal papilla cells (hDPCs) according to Experimental Example 1.
2 shows the results of measuring hair growth promotion-related mRNA expression in human dermal papilla cells (hDPCs) according to Example 2.
3 shows the results of evaluation of growth of hair follicle tissue using the Telogen to Anagen transition animal model according to Example 3 (observation at weekly intervals).
4 shows the results of evaluation of growth of hair follicle tissue using the Telogen to Anagen transition animal model according to Example 3 (observation at 7 weeks).

The present invention is to provide a pharmaceutical composition for preventing or treating hair loss and a pharmaceutical composition for promoting hair growth or hair growth, comprising boehmite as an active ingredient.

In the pharmaceutical composition according to the present invention, the boehmite is characterized in that it is a highly crystalline gamma boehmite according to Formula 1 below.

[Formula 1]

Al + H ₂ O → γ-AlOOH

The term "hair loss" as used herein may belong to this without special limitation if the number of hairs is less than the general number outside the normal hair growth level, and preferably, a group consisting of male-type hair loss, female-type hair loss, circular hair loss, and telogen hair loss. Any one or more selected from may correspond to hair loss treated or prevented by the composition according to the present invention. In addition, the composition according to the present invention is also excellent in preventing hair loss before hair loss begins.

As used herein, the term "hair growth" refers to hair growth, and "hair growth" refers to hair growth. The effect of the composition according to the present invention also includes the effect of promoting hair growth or hair growth.

The term "treatment" as used herein refers to any action in which symptoms due to hair loss are improved or advantageously changed by the composition of the present invention, and the term "prevention" refers to inhibiting or delaying hair loss by administration of the composition of the present invention. It means all actions.

The pharmaceutical composition of the present invention may further include suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions. In addition, the pharmaceutical composition according to the present invention is formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Can be used. Suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA.

Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

When formulating the pharmaceutical composition according to the present invention, it is prepared using diluents or excipients such as generally used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. in the active ingredient. It is prepared by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the individual, age, sex, type of disease , Drug activity, sensitivity to drugs, administration time, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all of the above factors, and can be easily determined by a person skilled in the art. The preferred dosage of the composition of the present invention varies depending on the condition and weight of the patient, the degree of disease, the form of the drug, the route and duration of administration, and the total amount of daily dosage can be determined by the treating physician within the correct medical judgment range, In general, an amount of 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, more preferably 0.1 to 100 mg/kg may be administered once or several times a day. It is not particularly limited as long as it is an individual for the purpose of preventing or treating hair loss, and any individual can be applied. For example, it can be applied to any individual such as non-human animals such as monkeys, dogs, cats, rabbits, mormots, rats, mice, cows, sheep, pigs, goats, and humans, but is not limited thereto.

The method of administering the pharmaceutical composition according to the present invention is not particularly limited, and may be administered orally or parenterally, and preferably may be administered parenterally. In the case of parenteral administration, it can be injected or injected intradermally, subcutaneously, intramuscularly, intravenously, intramedullary, intraarticular, synovial, intrathecal, or intrathecal, preferably subcutaneous, transdermal, or applied to the area of hair loss. Or it can be administered in the form of an application applied to the area where the progression of hair loss is predicted. In addition, since there is no particular limitation on the method of administration, it is also possible to directly inject in the form of injection to a site where hair loss or progression of hair loss is predicted. In addition, since there is no particular limitation on the method of administration, it is also possible to inject by injection into an artery or vein. The most preferred administration of the composition of the present invention may be through subcutaneous injection or skin application. In addition, the dosage level selected from the composition will depend on the activity of the active ingredient, the route of administration, the severity of the hair loss to be treated, and the condition and previous medical history of the hair loss to be treated. However, it is within the knowledge of the art to start with a dose of the active ingredient at a lower level than required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved, and the preferred dosage is age, It can be determined by gender, body type, and weight. The composition may be further processed prior to being formulated into a pharmaceutically acceptable pharmaceutical formulation, preferably pulverized or ground into smaller particles. Also, the composition will depend on the condition and the patient being treated, but this can be determined non-ingeniously.

The pharmaceutical composition of the present invention is a formulation that can be administered by a method such as direct application or dispersion to the skin, for example, hair or scalp, for example, a cream, lotion, ointment, aerosol, shampoo, gel, or pack. It may have a formulation of. Methods for formulations or formulations suitable for each formulation are well known in the art. When preparing these preparations, those skilled in the art can appropriately select and use various blending components used to prepare ordinary external preparations.

The hair to which the pharmaceutical composition of the present invention is applied includes all areas with hair roots and hair follicles of the head, hair and eyelashes and outer lashes, beard, armpits, pubic hair, and hair roots and hair follicles throughout the body.

In addition, the present invention is to provide a pharmaceutical composition for promoting hair growth or hair growth, comprising boehmite as an active ingredient.

In addition, the present invention is to provide a quasi-drug composition for preventing or improving hair loss comprising boehmite as an active ingredient.

In addition, the present invention is to provide a quasi-drug composition for promoting hair growth or hair growth, comprising boehmite as an active ingredient.

In the pharmaceutical composition and quasi-drug composition according to the present invention, the boehmite is characterized in that it is a highly crystalline gamma boehmite according to the following formula (1).

[Formula 1]

Al + H ₂ O → γ-AlOOH

The term "quasi-drug" used in the present invention refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating, or preventing diseases of humans or animals, weakly acting on the human body or not directly acting on the human body, Non-instrument or machine or similar, as an article corresponding to one of the preparations used for sterilization, insecticide, and similar purposes to prevent infection, for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals. It refers to items that are not instruments, machines, or devices among the items used, and items other than those that are not instruments, machines, or devices among items used for the purpose of having a pharmacological effect on the structure and function of a person or animal. Also includes hygiene products.

When the composition of the present invention is included in a quasi-drug for the purpose of preventing or improving hair loss, promoting hair growth or hair growth, the composition may be used as it is or may be used with other quasi-drug ingredients, and may be appropriately used according to a conventional method. have. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use.

The quasi-drug product of the present invention is not particularly limited thereto, but may be prepared and used in the form of, for example, a cream, lotion, aerosol, shampoo, gel or pack. In the case of creams, ointments, shampoos, gels or packs, white petrolatum, yellow petrolatum, lanolin, bleached beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, gelled hydrocarbons, polyethylene glycol, liquid paraffin, squalane, etc. The mechanism of; Solvents and dissolution aids, such as oleic acid, isopropyl myristic acid, glycerin triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipic acid, hexyl laurate, fatty acids, fatty acid esters, aliphatic alcohols, and vegetable oils; Antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; Preservatives such as parahydroxybenzoic acid ester; Moisturizing agents such as glycerin, propylene glycol, and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, and lecithin; And thickeners such as carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose. In the case of aerosols, white petrolatum, yellow petrolatum, lanolin, bleached beeswax, cetanol, stearyl alcohol, stearic acid, used in the preparation of ointments, creams, gels, suspensions, emulsions, liquids and lotions, etc. Bases such as hydrogenated oil, gelled hydrocarbons, polyethylene glycol, liquid paraffin, and squalane; Oleic acid, isopropyl myristic acid, diisopropyl adipate, isopropyl sebacate, glycerin triisooctanoate, crotamiton, diethyl sebacate, hexyl laurate, fatty acids, fatty acid esters, aliphatic alcohols, vegetable oils, etc. Solvents and dissolution aids; Antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; Preservatives such as parahydroxybenzoic acid ester; Moisturizing agents such as glycerin, propylene glycol, and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, and lecithin; Thickeners such as carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, carboxymethylcellulose sodium salt, hydroxypropylcellulose, and hydroxypropylmethylcellulose; In addition, various stabilizers, buffers, flavoring agents, suspending agents, emulsifiers, fragrances, preservatives, dissolution aids, and other suitable additives may be added.

Further, if necessary, a stabilizer, a preservative, an absorption accelerator, a pH adjuster, and other suitable additives may be added.

In addition, the present invention is to provide a cosmetic composition for preventing or improving hair loss and a cosmetic composition for promoting hair growth or hair growth, comprising boehmite composite particles as an active ingredient.

In the cosmetic composition according to the present invention, the boehmite is characterized in that it is a highly crystalline gamma boehmite according to Formula 1 below.

[Formula 1]

Al + H ₂ O → γ-AlOOH

The cosmetic composition is a skin external preparation formulation, such as hair tonic, hair cream, hair lotion, hair shampoo, hair conditioner, hair conditioner, hair spray, hair aerosol, pomade, powder gel, hair pack, hair treatment, eyebrow hair growth agent, eyelash hair growth agent, eyelashes It may be a nutritional formulation, but is not limited thereto.

The composition for preventing or improving hair loss, promoting hair growth or hair growth of the present invention may be used for pets in different formulations. For example, it can be prepared in various forms such as solutions, sol gels, emulsions, oils, waxes, aerosols, such as pet shampoos and pet rinses. It can be prepared by adding.

The cosmetic composition of the present invention may include, without limitation, ingredients that are generally permitted in addition to the active ingredients, and may include conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers. have.

In the case of a shampoo, it may contain a synthetic surfactant that is a cleaning component, and any one or more of a preservative, a thickener, a viscosity modifier, a pH modifier, a fragrance, a dye, a hair conditioning agent, and water. Among the synthetic surfactants, synthetic anionic surfactants are alkyl and alkyl ether sulfates, and representative examples include sodium lauryl sulfate, ammonium lauryl sulfate, triethanolamine lauryl sulfate, sodium polyoxyethylene lauryl sulfate, and ammonium polyoxyethylene lauryl sulfate. have. In addition, among the synthetic surfactants, synthetic amphoteric surfactants are alkyl betamine and alkyl amidopropyl betaine, and representative examples are cocodimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alpha-carboxyethyl betaine. , Cetyl dimethyl carboxymethyl betaine, and cocamido propyl betaine. The nonionic surfactants are alkanol amide and amine oxide, such as lauryl diethyl amine oxide, palm oil alkyldimethyl amine oxide, lauric acid diethanolamide, palm oil fatty acid diethanolamide, palm oil fatty acid monoethanolamide, and the like.

As an optional ingredient used in the present invention, it is widely known to experts in the art as a conventional optional ingredient for maintaining basic physical properties and quality as a shampoo. These optional ingredients include pearl foil adjuvants, preservatives, viscosity and viscosity modifiers, pH modifiers, fragrances, dyes, and hair conditioning agents. Pearl pearl adjuvants such as ethylene glycol monostearate and ethylene glycol distearate; Preservatives such as methyl para-oxyanate, a mixture of methylchloro isothiazolinone and methyl isothiazolinone; Thickeners and viscosity modifiers such as sodium chloride, ammonium chloride, propylene glycol; PH adjusters such as citric acid, phosphoric acid, sodium hydroxide, and potassium hydroxide; Hair conditioning agents such as polyquaternium-10, polyquaternium-7, methylpolysiloxane, dimethicone copolyol, hydrolyzed animal protein, dyes such as water-soluble tar are used, and fragrances may also be used.

In addition, the present invention is to provide a food composition for preventing or improving hair loss and a food composition for promoting hair growth or hair growth, comprising boehmite as an active ingredient.

In the food composition according to the present invention, the boehmite is characterized in that it is a highly crystalline gamma boehmite according to Formula 1 below.

[Formula 1]

Al + H ₂ O → γ-AlOOH

The food composition of the present invention may be in the form of a health functional food, and "health functional food" refers to a food manufactured and processed using raw materials or ingredients having useful functions for the human body according to No. 6727 of the Health Functional Food Act. It means, and "functional" refers to ingestion for the purpose of obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.

The food composition may additionally contain food additives, and the suitability as a "food additive" shall be determined according to the general rules of the Food Additive Code approved by the Korea Food and Drug Administration and general test methods, etc. It is judged according to the criteria.

Items listed in the "Food Additives Code", for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as red pigment, licorice extract, crystalline cellulose, and guar gum, L- Mixed preparations, such as a sodium glutamate preparation, an alkali additive for noodles, a preservative preparation, and a tar color preparation, are mentioned.

Foods containing the active ingredient of the present invention include bread, rice cakes, dried fruits, candies, chocolates, chewing gum, confectionery such as jam, ice cream products such as ice cream, ice cream, ice cream powder, milk, low-fat milk, lactose-decomposed milk, Processed milk, goat milk, fermented milk, butter milk, condensed milk, milk cream, butter oil, natural cheese, processed cheese, milk powder, dairy products such as whey products processed meat products, processed egg products, meat products such as hamburgers, fish cake, ham, Fish products such as processed fish products such as sausage and bacon, ramen noodles, dried noodles, raw noodles, milk-tang noodles, luxury dried noodles, improved soft noodles, frozen noodles, noodles such as pasta, fruit drinks, vegetable drinks, carbonated drinks, soy milk , Lactobacillus beverages such as yogurt, beverages such as mixed beverages Soy sauce, soybean paste, red pepper paste, Chunjang, Cheonggukjang, mixed sauce, vinegar, sauces, tomato ketchup, curry, seasoning foods such as margarine, shortening, and pizza. It is not limited.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, Carbonating agents used in carbonated beverages may be included. In addition, the composition of the present invention may include flesh for the manufacture of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination. Although the proportion of these additives is not very important, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The beverage composition including the active ingredient of the present invention is not particularly limited to other ingredients other than containing the protein, and may contain various flavoring agents or natural carbohydrates as an additional ingredient, as in ordinary beverages. Examples of the above-described natural carbohydrates include monosaccharides, (eg, glucose, fructose, etc.); Disaccharides, (eg maltose, sucrose, etc.); And polysaccharides, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have.

The present invention will be described in more detail by examples and experimental examples. However, the following Examples and Experimental Examples are illustrative so that the present invention can be more easily understood, and the contents of the present invention are not limited by the Examples, and at this time, unless there are other definitions in the technical and scientific terms used , It has the meaning generally understood by those of ordinary skill in the art to which this invention belongs.

<Test substance>

First, as the boehmite according to the present invention, a highly crystalline gamma boehmite (hereinafter referred to as “Jaielite SBM”) synthesized with only aluminum and DI Water as shown in Formula 1 below was used, and as a comparative example minoxidil: Minoxidil compound (sigma, in vitro), 3% Minoxidil, and Hyundai Pharmaceutical (in vivo) were used. On the other hand, the formulation of boehmite used in animal experiments was provided by “Obox EL Co., Ltd.”.

[Formula 1]

Al + H ₂ O → γ-AlOOH

<Example>

Example 1. Cell growth evaluation by Jaielite SBM using human dermal papilla cells (hDPCs)

In order to evaluate the cell proliferative effect of Jaielite SBM according to the present invention and the positive control minoxidil (MNX, Minoxidil), cell viability and Alkaline phosphatase (ALP) activation were investigated. Each sample was treated with hDPCs alone for 48 hours with MNX (10 μM), Jaielite SBM (100 ng/mL, 1 μg/mL, and 10 μg/mL). In addition, in order to evaluate the activity promoting effect of ALP, which is known as a marker for proliferation of hDPCs, the increase in ALP activity in hDPCs was investigated. As a result, it was confirmed that the cell viability and ALP activity were increased in the group treated with MNX and Jaielite SBM compared to the general control group in hDPCs (FIGS. 1A-B). As a result of observing the amount of protein expression using Western blot, it was found that the expression amount of hDPCs proliferation markers ALP and PCNA (Proliferating cell nuclear antigen) increased compared to the general control group in the group treated with MNX and Jaielite SBM (Fig. 1C- D). Therefore, it was proved that the treatment of Jaielite SBM can promote the growth of hDPCs, one of the key cells constituting the hair follicle tissue.

Example 2. Measurement of mRNA expression related to hair growth promotion in human dermal papilla cells (hDPCs)

In order to confirm the change in the expression of the gene expression related to the proliferation of seal human induced cells, the hDPCs were treated with MNX and Jaielite SBM for 24 hours, and then reverse transcription polymerase chain reaction (qRT-PCR) was performed on hDPCs proliferation-related genes: Alkaline phosphatase (ALP), Changes in the expression of β-Catenin, CyclinD1, Hey1, Lef-1, Shh (Sonic hedgehog), Sox2, Versican and VEGF were investigated. As a result, the mRNA levels of ALP, β-Catenin, CyclinD1, Hey1, Lef-1, Shh, Sox2, Versican, and VEGF were found to increase in the MNX and Jaielite SBM-treated groups.

Example 3. Hair follicle growth evaluation using a Telogen to Anagen transition animal model

The hair cycle is typically divided into telogen, anagen and catagen, while the period of the anagen determines the length of the hair produced by the hair follicle (hair follicle length growth continues). , The duration of the resting period determines the rate at which new follicles are formed (hair shaft length growth ceases). Therefore, the phenomenon of telogen-to-anagen or anagen-to-catagen transition must be strictly controlled as it contributes to the acquisition of optimal length and density of hair essential for survival and adaptation in many mammals.

Using a 6-week-old female mouse, the hair shaft of the back area was removed at the time of Telogen, and then the second anagen phase was observed, and the timing and speed of the formation of new hair follicles were compared and evaluated. Each sample was applied 5 times per week at 1 mL on the back of the mouse. The group of the animal model was formed into the general control group, the positive control group 3% minoxidil (MNX), the vehicle control group (Jaielite SBM 0%), Jaielite SBM 1%, Jaielite SBM 3%, Jaielite SBM 5%, Jaielite SBM 10% group.

As a result, 3% minoxidil, a positive control, showed a result that the skin color became dark starting at the 3rd week of treatment, resulting in the expected growth of the hair shaft. As time passed, the range gradually expanded and almost all parts became black at the 4th week. Appeared to change. In the case of Jaielite SBM, in the group treated with Vehicle Control (carrier control group, Jaielite SBM 0%), the skin color remained pink until the 7th week of observation, and hairs did not grow in almost all areas. However, in the comparative group containing the active ingredient (Jaielite SBM 1%, 3%, 5%, 10%), it was confirmed that the skin color became dark and hair shaft was formed at the beginning of the 4th week. It was observed that the formation of was increased (Fig. 3-4). Meanwhile, excellent hair shaft formation was evaluated in the group using more than 3% of the samples treated with Jaielite SBM, and it was confirmed that treatment with Jaielite SBM can accelerate the growth of hair follicles by advancing the time to enter the growth phase of the hair follicle in the mouse model. (Fig. 5).

As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, it is clear that these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereto. Therefore, it will be said that the practical scope of the present invention is defined by the appended claims and their equivalents.

Claims (12)

A pharmaceutical composition for preventing or treating hair loss and promoting hair growth or hair growth, comprising boehmite as an active ingredient.
The method of claim 1,
The boehmite is characterized in that the high crystal gamma boehmite according to the following formula (1), pharmaceutical composition.
[Formula 1]
Al + H ₂ O → γ-AlOOH
The method of claim 1,
The hair loss is characterized in that at least one selected from the group consisting of male-type hair loss, female-type hair loss, circular hair loss, and telogen hair loss.
The method of claim 1,
The pharmaceutical composition is characterized in that for parenteral administration, pharmaceutical composition.
A quasi-drug composition for preventing or improving hair loss and promoting hair growth or hair growth, comprising boehmite as an active ingredient.
The method of claim 5,
The quasi-drug composition is prepared in the form of a cream, lotion, aerosol, shampoo, gel or pack.
The method of claim 5,
The boehmite is characterized in that the high crystal gamma boehmite according to the following formula (1), quasi-drug composition.
[Formula 1]
Al + H ₂ O → γ-AlOOH
Cosmetic composition for preventing or improving hair loss and promoting hair growth or hair growth, comprising boehmite as an active ingredient.
The method of claim 8,
The boehmite is a cosmetic composition, characterized in that the high crystal gamma boehmite according to the following formula (1).
[Formula 1]
Al + H ₂ O → γ-AlOOH
The method of claim 8,
The cosmetic composition is made of hair tonic, hair cream, hair lotion, hair shampoo, hair conditioner, hair conditioner, hair spray, hair aerosol, pomade, powder gel, hair pack, hair treatment, eyebrow hair growth agent, eyelash hair growth agent, or eyelash nutrient. That, a cosmetic composition.
Food composition for preventing or improving hair loss and promoting hair growth or hair growth, comprising boehmite as an active ingredient.
The method of claim 11,
The boehmite is a food composition, characterized in that the high crystal gamma boehmite according to the following formula (1).
[Formula 1]
Al + H ₂ O → γ-AlOOH

Images